Author + information
- Received September 6, 1983
- Revision received March 28, 1984
- Accepted April 13, 1984
- Published online September 1, 1984.
- Edward J. Kosinski, MD*,1,
- Jonathan B. Albin, MD, FACC1,
- Eliot Young, MD1,
- Stanley M. Lewis, MD, FACC1 and
- O. Stevens LeLand Jr., MD1
- ↵*Address for reprints: Edward J. Kosinski, MD, Cardiology Section. New England Deaconess Hospital, 185 Pilgrim Road, Boston, Massachusetts 02215.
Amiodarone is a potent antiarrhythmic agent that is effective in controlling both atrial and ventricular arrhythmias. Recently, intravenous administration was demonstrated to be effective in the acute management of rhythm disorders and, in addition, appeared to shorten the loading period normally required for oral drug administration. This investigation examined the hemodynamic effects of amiodarone after both acute intravenous bolus and continuous intravenous administration. Patients with a left ventricular ejection fraction greater than 0.35 experienced improved cardiac performance due to both acute and chronic peripheral vasodilation. However, patients with a lower ejection fraction developed a 20% decrease in cardiac index and clinically significant elevation of right heart pressures after acute bolus administration; these changes were variably compensated for by peripheral vasodilation when the drug was administered intravenously over 3 to 5 days continuously. Therefore, intravenous amiodarone can result in significant impairment of left ventricular performance in patients with preexisting left ventricular dysfunction.
- Received September 6, 1983.
- Revision received March 28, 1984.
- Accepted April 13, 1984.
- American College of Cardiology Foundation